LTRN
Lantern Pharma Inc. Common Stock
$3.230+-0.000 (-0.000%)
Real-time Price
Price Chart
Loading Chart...
Key Metrics
Market Metrics
Open
$3.230
High
$3.230
Low
$3.230
Volume
0.11M
Company Fundamentals
Trading Stats
Related News
BusinessWire
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating
View more
BusinessWire
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern's AI platform,
View more
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.